Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Neuro-oncology

Recurrence, Clinical Trials, and Advanced Care

At a Glance

When glioblastoma returns, treatment focuses on maintaining quality of life and managing symptoms through salvage surgery, re-irradiation, or targeted drugs like Bevacizumab. Clinical trials offer access to new therapies, and early palliative care helps manage symptoms effectively.

Facing a recurrence—the return of the tumor—is a heavy and difficult moment in the glioblastoma journey. It is important to know that while the “standard” path of surgery and radiation may have already been used, there is still a wide range of salvage options available to manage the disease and maintain your quality of life.

Understanding the KPS Score

When considering treatments for a recurrence, doctors heavily rely on your Karnofsky Performance Status (KPS). This is a 0-100 scale that measures your ability to carry out normal daily activities and your level of independence. A score of 100 means normal functioning with no evidence of disease, while scores below 70 indicate a need for assistance with self-care [1]. A higher KPS score often makes a patient eligible for more aggressive treatments and clinical trials.

Surgical and Radiation Options

If the recurrence is localized to one area and your KPS is strong, your medical team may recommend repeating the treatments used initially:

  • Salvage Surgery (Re-operation): In selected patients, a second surgery to remove the recurring tumor can significantly prolong survival and relieve symptoms caused by pressure in the brain [2][3]. The goal remains the complete resection of enhancing tumor (CRET) while preserving brain function [4].
  • Re-irradiation: Advances in technology have made it possible to safely deliver radiation to the same area more than once. This can be done through localized stereotactic radiosurgery (SRS) or shorter, fractionated courses of radiation [5][6].

Systemic Therapies

When surgery or radiation is not the best fit, doctors turn to second-line medications.

  • Bevacizumab (Avastin®): This is one of the most commonly used drugs for recurrence. It works by “starving” the tumor of its blood supply [7].
    • The Benefit: Bevacizumab is highly effective at reducing brain swelling and the need for steroids, which significantly improves progression-free survival (the time you live without the tumor getting worse or causing symptoms) [8][9].
    • The Caveat: While it helps patients feel better and stay stable longer, studies have shown it does not consistently extend overall survival (the total length of time a patient lives) [9][10].
    • Side Effects: Patients taking bevacizumab should monitor for side effects such as high blood pressure, increased risk of bleeding, and issues with wound healing.
  • Regorafenib: This is a newer targeted therapy that may be offered to patients who have already tried bevacizumab or standard chemotherapy. It has shown promise in improving overall survival in some clinical trials, regardless of whether the tumor is MGMT-methylated or not [11][12].

The Critical Role of Clinical Trials

Because standard treatments for recurrence have limitations, clinical trials are often considered the preferred option by experts in neuro-oncology [13]. Trials provide access to cutting-edge therapies that are not yet available to the general public, including:

  • CAR-T Cell Therapy: Training your own immune cells to recognize and attack glioblastoma cells [14][15].
  • Oncolytic Viruses: Using modified viruses to “infect” and kill cancer cells while triggering an immune response [16].
  • Targeted Immunotherapy: New combinations of drugs designed to overcome the tumor’s ability to hide from the immune system [17][18].

Integrating Palliative Care Early

A common misconception is that palliative care is only for the end of life. In reality, palliative care is “supportive care” that should be integrated from the moment of diagnosis or recurrence [19][20].

  • What it does: Palliative care specialists focus on managing the complex symptoms of brain tumors—such as seizures, headaches, and mood changes—and reducing the burden on caregivers [21][22].
  • The impact: Research has shown that glioblastoma patients who receive specialized palliative care often have a higher quality of life and, in some cases, live longer than those who do not [23][24]. It is about living as well as possible, for as long as possible [25].

Common questions in this guide

What treatments are available if my glioblastoma comes back?
When glioblastoma returns, doctors may recommend salvage treatments based on your overall health and the tumor's location. Options can include a second surgery, targeted radiation, medications like bevacizumab or regorafenib, and enrolling in a clinical trial.
What is a KPS score and why does it matter?
The Karnofsky Performance Status (KPS) score measures your ability to perform daily activities and live independently. Doctors use this 0-100 scale to determine if you are healthy enough for certain aggressive treatments or eligible for clinical trials.
How does Bevacizumab (Avastin) help with recurrent glioblastoma?
Bevacizumab works by starving the tumor of its blood supply, which is highly effective at reducing brain swelling and steroid reliance. While it delays symptom progression and helps patients feel better, studies show it does not consistently extend overall survival.
Should I consider a clinical trial for a glioblastoma recurrence?
Because standard treatments for recurrence have limitations, experts in neuro-oncology often recommend clinical trials. These trials provide access to cutting-edge therapies that are not yet widely available, such as CAR-T cell therapy, oncolytic viruses, and targeted immunotherapy.
When should I start palliative care for glioblastoma?
Palliative care, also known as supportive care, should be integrated as early as the moment of diagnosis or recurrence. It focuses on managing complex brain tumor symptoms like seizures and headaches to maximize your quality of life, rather than just being for the end of life.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Am I a candidate for 'salvage surgery' or re-irradiation based on the location of the recurrence?
  2. 2.How will adding Bevacizumab (Avastin) change my symptoms versus my long-term outlook?
  3. 3.What is my current Karnofsky Performance Status (KPS), and how does that affect my eligibility for clinical trials?
  4. 4.Are there specific trials for 'molecularly targeted' therapies based on my original tumor markers?
  5. 5.Can we consult with the palliative care team now to help manage my symptoms while we pursue active treatment?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Prognostic Factors for Progression-free Survival and Overall Survival After Recurrence of Glioblastoma.

    Zemskova O, Yu NY, Leppert J, Rades D

    Anticancer research 2024; (44(7)):3059-3066 doi:10.21873/anticanres.17119.

    PMID: 38925836
  2. 2

    Survival after reoperation for recurrent glioblastoma multiforme: A prospective study.

    Furtak J, Kwiatkowski A, Śledzińska P, et al.

    Surgical oncology 2022; (42()):101771 doi:10.1016/j.suronc.2022.101771.

    PMID: 35512545
  3. 3

    Benefit of re-operation and salvage therapies for recurrent glioblastoma multiforme: results from a single institution.

    Azoulay M, Santos F, Shenouda G, et al.

    Journal of neuro-oncology 2017; (132(3)):419-426 doi:10.1007/s11060-017-2383-2.

    PMID: 28374095
  4. 4

    Current trends in reoperation for recurrent glioblastoma: a meta-analysis (2007-2023).

    Pichardo-Rojas PS, Garcia-Torrico F, Espinosa-Cantú CB, et al.

    Journal of neuro-oncology 2025; (174(2)):271-301 doi:10.1007/s11060-025-05058-1.

    PMID: 40314867
  5. 5

    Re-irradiation for recurrent glioblastoma (GBM): a systematic review and meta-analysis.

    Kazmi F, Soon YY, Leong YH, et al.

    Journal of neuro-oncology 2019; (142(1)):79-90 doi:10.1007/s11060-018-03064-0.

    PMID: 30523605
  6. 6

    Re-Irradiation and Its Contribution to Good Prognosis in Recurrent Glioblastoma Patients.

    Kim MS, Lim J, Shin HS, Cho KG

    Brain tumor research and treatment 2020; (8(1)):29-35 doi:10.14791/btrt.2020.8.e10.

    PMID: 32390351
  7. 7

    [Treatment of recurrent glioblastoma with single-agent bevacizumab].

    Sinkó D, Nemeskéri C

    Orvosi hetilap 2016; (157(13)):500-3 doi:10.1556/650.2015.30395.

    PMID: 26996897
  8. 8

    Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.

    Lombardi G, Pambuku A, Bellu L, et al.

    Critical reviews in oncology/hematology 2017; (111()):94-102 doi:10.1016/j.critrevonc.2017.01.018.

    PMID: 28259301
  9. 9

    Anti-angiogenic therapy for high-grade glioma.

    Ameratunga M, Pavlakis N, Wheeler H, et al.

    The Cochrane database of systematic reviews 2018; (11()):CD008218 doi:10.1002/14651858.CD008218.pub4.

    PMID: 30480778
  10. 10

    Efficacy of combined therapy with gamma knife radiosurgery and bevacizumab on survival outcomes in patients with recurrent high-grade glioma: a systematic review and meta-analysis.

    Aghedi M, Larijani A, Bagheri AB, et al.

    Neurosurgical review 2025; (48(1)):459.

    PMID: 40439764
  11. 11

    Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.

    Lombardi G, De Salvo GL, Brandes AA, et al.

    The Lancet. Oncology 2019; (20(1)):110-119 doi:10.1016/S1470-2045(18)30675-2.

    PMID: 30522967
  12. 12

    Current evidence and challenges of systematic therapies for adult recurrent glioblastoma: Results from clinical trials.

    Chen W, Liu D, Liu P, et al.

    Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2021; (33(3)):417-432 doi:10.21147/j.issn.1000-9604.2021.03.12.

    PMID: 34321837
  13. 13

    Systematic review and network meta-analysis of the efficacy of existing treatments for patients with recurrent glioblastoma.

    Schritz A, Aouali N, Fischer A, et al.

    Neuro-oncology advances 2021; (3(1)):vdab052 doi:10.1093/noajnl/vdab052.

    PMID: 34095835
  14. 14

    Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.

    Bagley SJ, Desai AS, Fraietta JA, et al.

    Nature medicine 2025; (31(8)):2778-2787 doi:10.1038/s41591-025-03745-0.

    PMID: 40451950
  15. 15

    Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.

    Bagley SJ, Logun M, Fraietta JA, et al.

    Nature medicine 2024; (30(5)):1320-1329 doi:10.1038/s41591-024-02893-z.

    PMID: 38480922
  16. 16

    Intratumoral oncolytic herpes virus G47∆ for residual or recurrent glioblastoma: a phase 2 trial.

    Todo T, Ito H, Ino Y, et al.

    Nature medicine 2022; (28(8)):1630-1639 doi:10.1038/s41591-022-01897-x.

    PMID: 35864254
  17. 17

    Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.

    Guo G, Zhang Z, Zhang J, et al.

    Cancer immunology, immunotherapy : CII 2024; (73(10)):193 doi:10.1007/s00262-024-03774-7.

    PMID: 39105794
  18. 18

    CAR T-cell therapy for gliomas.

    Song KW, Scott BJ

    Current opinion in neurology 2024; (37(6)):672-681 doi:10.1097/WCO.0000000000001318.

    PMID: 39498846
  19. 19

    Palliative Care in High-Grade Glioma: A Review.

    Crooms RC, Goldstein NE, Diamond EL, Vickrey BG

    Brain sciences 2020; (10(10)) doi:10.3390/brainsci10100723.

    PMID: 33066030
  20. 20

    "Life…Gets Turned Upside-Down…" Opportunities to Improve Palliative Care for High-Grade Glioma.

    Crooms RC, Nnemnbeng JF, Taylor JW, et al.

    Journal of pain and symptom management 2024; (68(3)):272-281.e2 doi:10.1016/j.jpainsymman.2024.06.001.

    PMID: 38866115
  21. 21

    Palliative Care Need and Quality of Life Mediated by Psychological Distress in Neurologic Diseases.

    Chan LML, Choi EPH, Lam WWT, et al.

    Journal of pain and symptom management 2025; (69(6)):641-653.e3 doi:10.1016/j.jpainsymman.2025.03.004.

    PMID: 40081623
  22. 22

    'It was never about me': A qualitative inquiry into the experiences of psychological support and perceived support needs of family caregivers of people with high-grade glioma.

    Lion KM, Jamieson A, Billin A, et al.

    Palliative medicine 2024; (38(8)):874-883 doi:10.1177/02692163241261211.

    PMID: 38916277
  23. 23

    Palliative care interventions and outcome in patients with glioblastoma - a retrospective, single-center study.

    Lind LM, Fischl A, Goettl E, et al.

    BMC palliative care 2026; (25(1)):29 doi:10.1186/s12904-026-01987-4.

    PMID: 41546074
  24. 24

    Effects of Integrating Palliative Care in Patients With Advanced Cancer: A Systematic Review and Meta-Analysis of Quality of Life and Psychological Outcomes.

    Bader H, Farraj H, Yamin S, et al.

    The American journal of hospice & palliative care 2025; (42(10)):1061-1072 doi:10.1177/10499091241297924.

    PMID: 39572903
  25. 25

    Living with glioblastoma - the need for integrated support based on experiences of chaos, loss of autonomy, and isolation in both patients and their relatives.

    Ståhl P, Henoch I, Rydenhag B, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2024; (32(9)):599 doi:10.1007/s00520-024-08801-y.

    PMID: 39167224

This information about glioblastoma recurrence and treatments is for educational purposes only. Always consult your neuro-oncology team to determine the best treatment plan or clinical trial for your specific situation.

Get notified when new evidence is published on Glioblastoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.